Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Teleflex Incorporated

TFX

Teleflex Inc is a provider of medical technology products focused on enhancing clinical benefits, improving patient and provider safety and reducing total procedural costs. It designs, develops, manufactures and supply medical devices used by hospitals and healthcare providers supporting high-acuity emergent procedures. The company has three reportable segments: Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). It derives maximum revenue from Americas. Its products includes: Anaesthesia, Emergency Medicine, Interventional Cardiology/Radiology, Interventional Urology - UroLift System, Surgery, Urology, and Vascular Access.

Last trade $159.55
Day change +$2.45 (+1.56%)
Day range $154.05 – $162.68
Volume 628,880
Market cap $6.23B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$6.23B
Price / earnings
6.11×
Price / book
1.78×
Price / sales
3.69×
EV / sales
4.41×
EV / EBITDA
22.06×

Profitability

Earnings per share
$25.69
Return on assets
16.05%
Return on equity
29.17%
Dividend yield
0.94%

Liquidity and leverage

Debt / equity
0.47×
Current ratio
2.28×
Quick ratio
1.81×
Cash ratio
0.53×

Cash flow

Price / cash flow
14.05×
Price / free cash flow
16.05×
Free cash flow
$388.23M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for TFX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 28, 2025Q2 FY2025 Jun 29, 2025Q1 FY2025 Mar 30, 2025Q4 FY2024 Dec 31, 2024
Revenue$567.78M$570.33M$548.26M—$566.95M$442.53M$414.26M$795.41M
Cost of revenue$199M$238.63M$240.84M$0$274.9M$176.7M$158.83M$355.49M
Gross profit$368.79M$331.71M$307.43M—$292.05M$265.83M$255.43M$439.92M
Selling, general and administrative$220.72M$213.52M$226.01M—$207.38M$137.5M$152.91M$254.55M
Research and development$42.98M$45.12M$44.39M—$44.26M$26.49M$25.3M$44.55M
Total operating expenses$263.36M$258.88M$287.24M—$354.48M$174.69M$179.63M$550.3M
Operating income$105.43M$72.82M$20.18M—-$62.44M$91.14M$75.8M-$110.38M
Interest expense-$21.21M-$27.95M-$25.72M—-$31.83M-$21.7M-$18.54M-$18.64M
Income before taxes$83.12M$45.14M-$3.83M—-$92.44M$70.66M$58.75M-$126.76M
Income taxes$246.17M$3.38M$1.01M—-$29.7M$2.49M$6.42M$9.9M
Net income$927.43M$102.02M-$8.15M—-$408.89M$132.75M$95M-$136.66M
Net income attributable to common shareholders$927.43M$99.69M-$8.15M—-$408.89M$122.58M$95M-$136.66M
EBITDA$156.66M$122.89M$90.77M-$33.23M$89.06M$138.73M$115.84M$99.53M
Basic earnings per share$22.36$2.29-$0.18—-$9.24$2.77$2.08-$2.94
Diluted earnings per share$22.28$2.28-$0.18—-$9.24$2.77$2.07-$2.93

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Steris (STE) Q2 Earnings and Revenues Surpass Estimates

Steris reported quarterly earnings of $2.94 per share, beating consensus estimates of $2.67 and surpassing year-ago earnings of $2.47. The company also exceeded revenue expectations with $1.59 billion versus consensus of $1.56 billion. Despite strong earnings performance, Steris shares have underperformed the S&P 500 by 19.3% year-to-date. The stock holds a Zacks Rank #2 (Buy) rating based on favorable estimate revision trends.

GlobeNewswire Inc.

China Airway Management Market Forecast to 2033 - Airway Management Tubes and Intubation Accessories | Revenue, Volume, Pricing, Company Share, and Growth Opportunities

ResearchAndMarkets.com released a comprehensive market report on China's airway management sector, covering historical data from 2018 and forecasts through 2033. The report segments the market into Airway Management Tubes and Intubation Accessories, providing revenue, volume, and pricing analysis. It includes 2025 company share data and profiles of key competitors to support strategic planning and investment decisions in this growing medical device market.

Zacks Investment Research

Bruker Gains 66.3% in a Year: What's Driving the Rally?

Bruker Corporation (BRKR) shares gained 66.3% over the past year, driven by strong demand in biopharma, diagnostics, and mass spectrometry. However, the company faces a $134.9M goodwill impairment, currency headwinds, and restructuring costs. Full-year 2026 revenue guidance was lowered to $3.54-$3.57B due to currency pressures, though the company maintains a solid financial position with $184.9M in cash.

Zacks Investment Research

Reasons to Add Globus Medical Stock to Your Portfolio Now

Globus Medical (GMED) reported strong Q2 2026 performance with musculoskeletal revenues rising 7.5% and base business sales up 10.9%. The company continues to gain market share through product innovation, with over 60 development projects underway. However, foreign exchange volatility remains a concern. GMED maintains a debt-free balance sheet with $507.7 million in cash, supporting continued R&D and expansion investments.

Zacks Investment Research

Charles River Gains 75.8% in a Year: What's Driving the Rally?

Charles River Laboratories (CRL) has outperformed the market with a 75.8% share price increase over the past year, driven by strong Research Models and Services (RMS) prospects and adoption of new approach methodologies. However, the company faces headwinds from uneven demand recovery across client segments, with small and midsized biotech revenues flat and currency fluctuations impacting reported growth. The company maintains a Zacks Rank #3 (Hold) rating.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Nov 16, 2026$0.34Dec 31, 2026recurring
Aug 14, 2026$0.34Sep 30, 2026recurring
May 22, 2026$0.34Jun 30, 2026recurring
Mar 6, 2026$0.34Mar 31, 2026recurring
Nov 14, 2025$0.34Dec 15, 2025recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.